Skip to main content
Equibles

MDWD · MediWound Ltd.

Track MDWD — free

Use MDWD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDWD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.11 -0.60 (-4.38%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$169.25M
Shares
12.91M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$13.11 Open$13.81 Day$12.95–13.81 52W close$12.61–19.69 Avg vol 30d98K Short int1.6M · 12.6% float · 14.4d Short vol83% Last earningsAug 13, 2026 DataDec 2022–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Dec 20, 2022; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 8 wks

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+12.7%
Year over year
Operating margin
-149.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.9%
Year over year · more shares
Price change (1Y)
-25.7%
Trailing year
Short interest
12.6%
Latest settlement · 14.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg −6%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 7%
near low
Momentum
relative strength
Very Weak
1-month return −3%
trailing
6-month return −23%
trailing
YTD return −29%
this year
Relative strength −41%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +14 funds added
Insider flow Distributing
Net -$75.4K over 90 days · 67% sells
Short interest Rising
12.61% of float · ▲ +2.5% MoM · 14.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
78 holders — near 3-yr high, broad support
Squeeze score 73
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 40%
annualized · 1-yr
Max drawdown −36%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2026
Full year 2026 revenue · full year 2026 Initiated $24M – $26M
Prior guidance period ended · from the Earnings Call filed Dec 31, 2021
Cash burn · 2022 $11M – $13M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
−6% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
7% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $14 › 200d $16 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +14 funds added
Insider flow Distributing
Net -$75.4K over 90 days · 67% sells
Short interest Rising
12.61% of float · ▲ +2.5% MoM · 14.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
78 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $13 · 7% Range high $20
vs 200-day avg -19% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MDWD
MediWound Ltd.
this stock
$169.25M -29.0% — — 12.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
78
% held
45.3%
Net QoQ
-248.6K sh
Top holder
INVESTOR AB
Held Float
View
Held by Funds
Fund positions
18
View
Short & Settlement
Short Interest Rising
Shares short
1.6M
Days to cover
14.4d
Change
+39.8K sh
View
Short Volume
Short vol %
83%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5.4K
Value
$72.5K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
33.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$75.4K
Buyers / Sellers
1 / 2
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 13, 2026
This year
10
View
Proposed Sales
Value
$50.3K
Shares
4.0K
Filed
Aug 28, 2026
View
Exempt Offerings
Offering
$17.2M
Filed
Oct 6, 2022
View
Earnings & Events
Earnings Calls
Last call
Aug 13, 2026
View

Performance

Raw-price comparisons begin at the captured split on Dec 20, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
MDWD -0.8% -3.1% -22.7% +4.0% -29.0%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +0.4% -1.4% -40.5% +4.3% -41.1%
Key facts CIK 1593984 CUSIP M68830112 13F (30d) 33 filings 33 filers Visit website Investor relations